Zevra Therapeutics, Inc. (ZVRA) has disclosed a new risk, in the Accounting & Financial Operations category.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zevra Therapeutics, Inc. has recently recognized an impairment charge of $58.7 million related to its definite-lived intangible assets for the quarter ending June 30, 2025. This financial adjustment highlights the potential risk of further impairments, which could adversely impact the company’s operating results. The evaluation of potential impairment involves significant judgment, considering factors such as changes in asset utilization, economic trends, and performance metrics. Future impairments could arise from these variables, posing a risk to the company’s financial stability.
The average ZVRA stock price target is $22.29, implying 136.37% upside potential.
To learn more about Zevra Therapeutics, Inc.’s risk factors, click here.